Genomic screening of the Embryo for Novel targets in the tumor Endothelium



ORCID researcher ID


Marie Curie Actions -

Intra-European Fellowship





Dr. Elisabeth J.M. Huijbers


Postdoctoral fellow

Department of Medical Oncology, VU University Medical Center,

Cancer Center Amsterdam, The Netherlands


EU Marie Curie postdoctoral fellow (GENE, FP7-PEOPLE-2012-IEF)

Department of Medical Oncology, VU University Medical Center,

Cancer Center Amsterdam, The Netherlands


Postdoctoral fellow (May 2012 - April 2013)

Department of Medical Biochemistry and Microbiology,

Uppsala University, Sweden

Project: Development of a cancer vaccine targeting tumor blood vessels

Research group of Associate Professor Dr. Anna-Karin



PhD degree (11 May 2012): Medical Faculty, Uppsala University, Sweden

PhD thesis: Development of a cancer vaccine targeting tumor blood vessels

Supervisor: Associate Professor Dr. Anna-Karin Olsson


Licentiate degree (4 March 2010): Medical Faculty, Uppsala University, Sweden, 2010-03-04

Licentiate thesis: Targeting tumor vessels by therapeutic vaccination

Supervisor: Associate Professor Dr. Ann-Karin Olsson


Master of pharmaceutical sciences degree (23 November 2005):

Faculty of Science, Utrecht University, The Netherlands, 2005-11-23


‘Doctoraal’* degree in pharmaceutical sciences (year 2003):

Faculty of Science, Utrecht University, The Netherlands, 2003


*equivalent to bachelor degree, but 4-year education



Research Project (September 2007 - February 2008):

Development of a cancer vaccine targeting tumor blood vessels

Department of Immunology, Genetics and Pathology, Uppsala University, Sweden

Supervisor: Associate Professor Dr. Anna-Karin Olsson


Internship (August 2005; 4 weeks): literature search about methadone programs and writing of a grant application for funding of an inter-disciplinary education program

College of Pharmacy and Nutrition, University of Saskatchewan, Canada

Supervisor: Professor Dr. Roy Dobson


Master thesis (August 2002 - February 2003): Qualitative and quantitative analysis of drug efflux-proteins in different cell lines

Department of Pharmacy, Uppsala University, Sweden

Research group of Professor Dr. Per Artursson, supervisor: Dr. Ann-Cathrin Engwall



Community pharmacist and store manager (January 2006 - July 2007): community pharmacist in Zaltbommel and manager of a small pharmacy store in Gameren

Employer: Marjolein Menheere, Stadsapotheek Zaltbommel B.V., Zaltbommel, The Netherlands



Saupe F, Huijbers EJM, Hein T, Femel J, Cedervall J, Olsson AK, Hellman L. Vaccines targeting self-antigens: mechanisms and efficacy-determining parameters. (2015) FASEB J. [Epub ahead of print]


Huijbers EJM, Paulis Y, Soetekouw P, Tjan-Heijnen P, Griffioen AW. CD44 determines tumor cell aggressiveness. (2015) Oncotarget

[Epub ahead of print]


van Beijnum JR, Nowak-Sliwinska P, Huijbers EJM, Thijssen VL, Griffioen AW. The great escape; the hallmarks of resistance to antiangiogenic

therapy. (2015) Pharmacol Rev. 67:441-61


Wentink, MQ, Huijbers EJM, De Gruijl, TD, Verheul, HM, Olsson AK, Griffioen AW. Vaccination approach to angiostatic therapy. (2015) BBA Cancer, 1855:155-171


Femel J, Huijbers EJM, Saupe F, Cedervall J, Zhang L, Roswall P, Larsson E, Olofsson H, Pietras K, Dimberg A, Hellman L, Olsson AK. Therapeutic vaccination against fibornectin ED-A attenuates progression of metastatic breast cancer. (2014) Oncotarget 5:12418-27


Huijbers EJM, Ringvall M, Femel J, Kalamajski S, Lukinius A, Åbrink M, Hellman L. and Olsson AK. Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. (2010) FASEB J. 24: 4535-44.


Huijbers EJM, Femel J, Andersson K, Björkelund H, Hellman L. and Olsson AK. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund’s in a cancer vaccine targeting ED-B – a prerequisite for clinical development. (2012) Vaccine 30: 225-230.


Ringvall M, Huijbers EJM, Ahooghalandari P, Alekseeva L, Andronova T, Olsson AK, Hellman L. Identification of potent biodegradable adjuvants that efficiently break self- tolerance - a key issue in the development of therapeutic vaccines. (2009) Vaccine 28: 48-52.


Huijbers EJM, Baars JW, Schutte PF, Schellens JH, Beijnen JH. Propofol extravasation in a breast cancer patient. (2008) J Oncol Pharm Pract. 14: 195-8.


Boer S de*, Dingemans JA*, Huijbers EJM*, Zych TR*, Beijnen JH. De keerzijde van succes. Late cardiotoxiciteit bij antracyclinegebruik (The downside of succes. Late cardiotoxicity after anthracycline use). (2006) Pharmaceutisch Weekblad (Dutch Pharmaceutical Journal) 37: 1154-1157 *Equal contribution.


Huijbers EJM, De ontwikkeling van een vaccin dat aangrijpt op de tumorangiogenese (Development of a vaccine targeting tumor angiogenesis). (2012) Pharmaceutisch Weekblad Wetenschappelijk Platform 6:a1224





Disclaimer: E. Huijbers, updated 15 October 2014